CENTOGENE to receive license fee providing Evotec with R&D license to complete next phase of pre-clinical researchCompanies amend existing drug discovery partnership for Evotec to lead continued development. Upon Evotec exercising its option, CENTOGENE to receive an option exercise fee and other potential milestone payments and royalties CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, May 14, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-dr
One of the biggest stories of last week was how Evotec SE ( ETR:EVT ) shares plunged 32% in the week since its latest...
Evotec ( ETR:EVT ) Full Year 2023 Results Key Financial Results Revenue: €781.4m (up 4.0% from FY 2022). Net loss...